US20100217180A1 - Simulation of patient drain phase in peritoneal dialysis - Google Patents
Simulation of patient drain phase in peritoneal dialysis Download PDFInfo
- Publication number
- US20100217180A1 US20100217180A1 US12/389,886 US38988609A US2010217180A1 US 20100217180 A1 US20100217180 A1 US 20100217180A1 US 38988609 A US38988609 A US 38988609A US 2010217180 A1 US2010217180 A1 US 2010217180A1
- Authority
- US
- United States
- Prior art keywords
- drain
- patient
- segment
- time
- volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000502 dialysis Methods 0.000 title claims abstract description 37
- 238000004088 simulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 33
- 238000002560 therapeutic procedure Methods 0.000 claims description 30
- 230000005484 gravity Effects 0.000 claims description 10
- 238000007562 laser obscuration time method Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000011148 porous material Substances 0.000 description 15
- 230000007704 transition Effects 0.000 description 11
- 210000003200 peritoneal cavity Anatomy 0.000 description 10
- 230000008901 benefit Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000002699 waste material Substances 0.000 description 6
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/282—Operational modes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
Definitions
- the present disclosure relates to medical fluid delivery and in particular to peritoneal dialysis fluid delivery.
- urea urea, creatinine, uric acid, and others
- Kidney failure and reduced kidney function have been treated with dialysis. Dialysis removes waste, toxins and excess water from the body that would otherwise have been removed by normal functioning kidneys. Dialysis treatment for replacement of kidney functions is critical to many people because the treatment is life saving. One who has failed kidneys could not continue to live without replacing at least the filtration functions of the kidneys.
- peritoneal dialysis uses a dialysis solution or “dialysate”, which is infused into a patient's peritoneal cavity through a catheter implanted in the cavity.
- the dialysate contacts the patient's peritoneal membrane in the peritoneal cavity.
- Waste, toxins and excess water pass from the patient's bloodstream through the peritoneal membrane and into the dialysate.
- the transfer of waste, toxins, and water from the bloodstream into the dialysate occurs due to diffusion and osmosis, i.e., an osmotic gradient occurs across the membrane.
- the spent dialysate drains from the patient's peritoneal cavity and removes the waste, toxins and excess water from the patient. This cycle is repeated.
- CAPD continuous ambulatory peritoneal dialysis
- APD automated peritoneal dialysis
- CAPD is a manual dialysis treatment, in which the patient connects an implanted catheter to a drain and allows a spent dialysate fluid to drain from the patient's peritoneal cavity. The patient then connects the catheter to a bag of fresh dialysate and manually infuses fresh dialysate through the catheter and into the patient's peritoneal cavity. The patient disconnects the catheter from the fresh dialysate bag and allows the dialysate to dwell within the cavity to transfer waste, toxins and excess water from the patient's bloodstream to the dialysate solution. After a dwell period, the patient repeats the manual dialysis procedure.
- CAPD CAPD the patient performs several drain, fill, and dwell cycles during the day, for example, about four times per day. Each treatment cycle typically takes about four to five hours.
- APD is similar to CAPD in that the dialysis treatment includes a drain, fill, and dwell cycle.
- APD machines perform four to five cycles of peritoneal dialysis treatment automatically, typically overnight while the patient sleeps.
- APD machines connect fluidly to an implanted catheter, to one or more sources or bags of fresh dialysate and to a fluid drain.
- the APD machines pump fresh dialysate from the dialysate source, through the catheter, into the patient's peritoneal cavity and allow the dialysate to dwell within the cavity so that the transfer of waste, toxins and excess water from the patient's bloodstream to the dialysate solution can take place.
- the APD machines then pump spent dialysate from the peritoneal cavity, though the catheter, to the drain.
- APD machines are typically computer controlled so that the dialysis treatment occurs automatically when the patient is connected to the dialysis machine, for example, when the patient sleeps. That is, the APD systems automatically and sequentially pump fluid into the peritoneal cavity, allow for a dwell, pump fluid out of the peritoneal cavity and repeat the procedure. As with the manual process, several drain, fill, and dwell cycles will occur during APD.
- a “last fill” is typically used at the end of APD, which remains in the peritoneal cavity of the patient when the patient disconnects from the dialysis machine for the day.
- the therapy must allow for a certain amount of time for the patient drain phase. It is important that the drain phase be sufficiently long to allow the patient to drain as completely as possible. On the other hand, if too much time is allowed for the drain phase, that is, the patient is basically finished draining too far in advance of the end of the drain phase, then the drain phase is extending needlessly into time that the patient could be filling or is appending the last fill's dwell phase needlessly.
- the present disclosure sets forth a method and apparatus for predicting a patient's optimal drain phase time.
- the optimal drain phase time is useful for at least two purposes.
- the optimal drain phase time can be implemented into the patient's continuous ambulatory peritoneal dialysis (“CAPD”) or automated peritoneal dialysis (“APD”) treatment.
- the optimal drain phase time can be used in the further modeling of possible treatments or therapy regimes for the patient, one or more desirable ones of which can then be selected for actual use.
- the further treatment or prescription modeling can be done using a three-pore model as discussed below.
- the drain phase modeling attempts to match the patient's actual drain profile given certain inputs.
- One important patient specific input is maximum drain flowrate or Q max .
- Q max typically occurs at the start of the drain. Some patients will drain more quickly than others due to patient-specific physical characteristics. Also, the position of the patient affects Q max . A patient standing or sitting may drain quicker than if the same patient is lying down in a supine or prone position.
- Q max is determined in one embodiment by experimentation with the patient in a drain position that the patient expects to be for at least most treatments.
- FIGS. 1 and 2 typical drain volume and corresponding flowrate profiles, respectively, are shown.
- the profiles were derived in a study by Brandes J. C., Packard, J. W., Watters S. K., Fritsche C., Optimization of Dialysate Flow and Mass Transfer During Automated Peritoneal Dialysis, American Journal of Kidney Diseases, Vol. 25, No. 4 (April), 1995, pp. 603-610.
- FIG. 1 shows a constant drop in drain volume from a full volume of about 2000 ml to a transition drain volume of about 350 to 400 ml.
- This constant drop occurs while flowrate is generally at a maximum, e.g., Q max , which is about 350 ml/min as seen in FIG. 2 .
- Q max a maximum
- the volume drains according to a decaying exponential curve. Drain flowrate after the transition point also slows to zero according to a similar curve.
- the transition point in both FIGS. 1 and 2 separates a first segment from a second segment as discussed in detail below.
- an equation has been formed that models the first and second segments.
- the equation relies principally on Q max for the first segment.
- the equation employs a switching component ⁇ that either (i) switches the first segment portion of the equation on and the second segment portion of the equation off or (ii) switches the first segment portion of the equation off and the second segment portion of the equation on.
- the transition time (or volume) at which switching component ⁇ switches from 1 to 0 is determined empirically, e.g., the duration of the constant high flow Qmax can be measured for each individual patient, and for a particular drain position.
- the second segment portion of the equation also employs an exponential drain rate constant ⁇ , which is patient specific and is determined empirically. The equation relies principally on a for the second segment.
- the drain modeling equation can be used in a number of ways. First, it can be used to form individual settings for flowrate threshold (“FRT”) and/or minimum drain volume (“MDV”). One or both of FRT and MDV may be set as alarm limits in an automated peritoneal dialysis (“APD”) machine (which can use either gravity draining or pumped draining).
- FRT flowrate threshold
- MDV minimum drain volume
- APD automated peritoneal dialysis
- the drain modeling equation can be used to more accurately model a patient's reaction to therapy, e.g., via a three-pore model.
- the three-pore model uses a drain time (or dwell time, which is a function of drain time) in one or more places to model a particular patient's reaction to a particular therapy prescription.
- the drain modeling equation can be used to set drain and dwell times or periods for actual operation of an APD machine, for example, performing a multiple exchange therapy.
- the machine can be a gravity drain machine or drain via a pump.
- the drain modeling equation can be used to set drain times or periods for patients performing manual peritoneal dialysis or CAPD.
- FIGS. 1 and 2 are drain volume and drain phase flowrate profiles derived from actual patient data via a study.
- FIGS. 3 and 4 are drain volume and drain phase flowrate profiles derived via the modeling method and apparatus of the present disclosure.
- FIG. 5 is a schematic diagram illustrating how the drain volume modeling method and apparatus of the present disclosure is used with kinetic modeling of patient therapy outcomes, e.g., using a three-pore model.
- FIGS. 6A to 6C illustrate a first therapy modeled via kinetic model using information obtained from the drain volume modeling method and apparatus of the present disclosure.
- FIG. 7 is a graph illustrating peritoneal volume over time for the therapy illustrated in FIGS. 6A to 6C .
- FIGS. 8A to 8C illustrate a second therapy modeled via kinetic model using information obtained from the drain volume modeling method and apparatus of the present disclosure.
- FIG. 9 is a graph illustrating peritoneal volume over time for the therapy illustrated in FIGS. 8A to 8C .
- drain volume modeling method and apparatus of the present disclosure uses the concepts and terminology described below.
- Maximum drain flowrate, Q max is the initial drain flowrate, which should be a maximum flowrate of the drain flowrate profile.
- the present disclosure applies to different kinds of APD machines.
- the APD machine can use a gravity fill and drain, in which the supply bag is placed elevationally above the patient and the drain bag is placed elevationally below the patient.
- Q max is determined empirically as discussed below.
- Q max is also determined empirically for continuous ambulatory peritoneal dialysis (“CAPD”), which also uses gravity for filling and draining.
- the HomeChoice® machine made by the assignee of the present disclosure, pumps spent fluid from the patient to drain.
- Q max is set by the pump speed, does not need to be determined empirically, and is independent of the patient's drain position.
- Q max is assumed to remain constant until the patient drain transitions to an exponential decay portion or segment of the profile.
- Q max is patient specific and is also patient drain position specific.
- Q max is determined empirically by, for example, weighing the patient's drain over time for a number of exchanges and then averaging the resulting rate.
- Q max may vary for a patient depending upon whether the patient is sitting, laying down or standing during drain. It is contemplated therefore to obtain empirical data for Q max while the patient is positioned for drain in a position that the patient intends to be for most or all drains.
- an automated peritoneal dialysis (“APD”) machine can be programmed to ask the patient which drain position the patient intends to use for the current treatment.
- Flow transition percent is the percentage of the peritoneal volume at which the patient drain transitions from the first segment, having constant drain flowrate Q max , to the second segment having the decaying exponential flowrate.
- FTP sets the volume (or percentage of total time) at which switching component ⁇ , discussed in detail herein, switches from 1 to 0.
- FTP is patient specific and is determined empirically regardless of the type of APD machine (gravity drain or pump to drain) used. FTP may also be dependent upon patient drain position for gravity fed systems or treatments.
- the second drain profile segment having the decaying exponential flowrate, is controlled in large part by a decaying exponential constant ⁇ , which is also patient specific and is determined empirically regardless of the type of APD machine (gravity drain or pump to drain) used or if CAPD is performed instead.
- ⁇ itself may depend on drain type, pump or gravity, and perhaps pump type, e.g., peristaltic versus membrane.
- ⁇ may also be dependent upon patient drain position for gravity fed systems or treatments.
- ⁇ is determined by obtaining multiple data points (volume for a given time and flowrate for a given time) during the second or decaying exponential drain flow and volume segment.
- ⁇ can for example be in a range of 0.1 to 0.15.
- MDP minimum drain percentage
- MDP sets a drain limit above which the patient's drain volume must reach during the drain phase. If, for example, the patient does not drain at least eighty percent of the total spent volume in the patient's peritoneum, The APD will sound an alarm and therapy may be halted, preventing the machine from advancing to the next fill phase until the low drain is addressed.
- MDP can be used with the modeled drain profiles to determine an appropriate dwell time for the patient, in particular, it sets a minimum dwell time to reach MDP
- Flowrate threshold may also be set in the software of an APD machine for alarm purposes.
- FRT sets a minimum drain flowrate level below which the machine may alarm, for example, indicating that the drain flowrate is so low that the treatment in essence is wasting time by continuing drain.
- FRT can alternatively be set to define a drain flow limit below which the drain is stopped.
- FTP and MDP can be used, alone or in combination, with the modeled drain profiles to determine an appropriate dwell time for the patient, which ensures that the dwell time is long enough for MDP to be met but does not continue long enough for the drain flowrate to fall below FTP.
- drain volume and drain flowrate profiles are shown, respectively, which have been modeled to attempt to match the actual drain volume and drain flowrate profiles of FIGS. 1 and 2 .
- the drain volume profile of FIG. 3 is obtained via the following equation or algorithm:
- V D [V D0 ⁇ Q max *t]* ⁇ +[V D0 *e ⁇ t ]*(1 ⁇ ), wherein
- V D is an instantaneous remaining drain volume in the patient at time t
- V D0 is an initial patient drain volume (fill volume plus UF accumulated over previous dwell);
- ⁇ discussed above is a switching component (from 1 to 0 at FTP), which is based on time or volume;
- t is time.
- the modeled flowrate profile of FIG. 4 is determined by dividing a change in volume by a corresponding change in time, e.g., drop from 2300 ml to 2600 ml over first two minutes leading to flowrate over that period of 350 m/min.
- Specific flowrate values can be obtained via a derivative dV/dT, especially in the second, non-linear, segment.
- V D0 is the previous fill volume plus an amount of ultrafiltrate (“UF”) removed from the patient over the last dwell.
- the amount of UF can be estimated via a three-pore model given certain parameters, such as patient physiological characteristics (ability to remove UF), dextrose level of dialysate used and dwell time. For example, if the patient fill is 2000 ml of fresh dialysate and it is determined from a patient kinetic model, such as a three-pore model, or perhaps experimentally, that the patient will acquire 300 ml of ultrafiltrate over the course of a known dwell period, V D0 will be set to 2300 ml.
- Q max is determined empirically or set via pump speed.
- a schematic showing fill, dwell and drain phases of a peritoneal dialysis treatment illustrates how the drain volume modeling method and apparatus of the present disclosure interfaces with the kinetic modeling of patient therapy outcomes, e.g., using a three-pore model.
- the duration of the fill phase in APD is set via a pump speed.
- the duration of the fill phase in CAPD is determined principally by head height of the fill bag above the patient.
- Dwell phase duration and drain phase duration are related.
- a treatment typically requires multiple, e.g., four, fills that are made over an entire treatment, e.g., eight hours.
- the set fill times leave only so much time for the dwell and drain phases. The less time needed for drain, the more time left for dwell, which is desirable from both clearance and UF standpoints.
- FIGS. 6A to 6C one example therapy modeled using a three-pore kinetic model is illustrated.
- the three-pore kinetic model used drain times selected from drain volume and drain flowrate profiles, similar to FIGS. 3 and 4 , which were determined via the equation above.
- the patient undergoes four exchanges of two liter fills each, totaling eight liters.
- PET characteristic is H or high meaning the patient in general has high toxin and glucose clearances.
- FIG. 6B A modeled drain time and corresponding drain volume is shown for each cycle in FIG. 6B .
- the drain volume met the MDP requirement of 85%
- the minimum drain flowrate met the FRT requirement of 75 ml/min, both of which are shown in FIG. 6A .
- FIG. 6A also shows patient specific parameters, namely, an FTP of 75% (percentage of drain after which switching component ⁇ changes from 1 to 0) and a Q max of 80 ml/min.
- the drain time and drain volume selected vary from cycle to cycle because initial drain volume V D0 varies from cycle to cycle.
- Initial drain volume V D0 varies from cycle to cycle because residual volume (volume remaining in the patient's peritoneum after drain is completed) varies from cycle to cycle.
- residual volume jumps from 150 ml after cycle 1 to 537 ml for cycle 2 and then increases more slowly to 631 ml and 654 ml for cycles three and four.
- FIG. 6C shows the three-pore kinetic model's predicted UF removed for the therapy of FIG. 6B .
- FIG. 6B and FIG. 7 (graphing peak volume over the cycles) highlight one concern about the “four exchange each of a two liter fill” therapy of FIG. 6B , namely, that the predicted peak volume of the patient indicates the patient may become overfilled.
- a peak volume of roughly 2700 ml may be too high for many patients.
- FIGS. 8A to 8C a second example therapy modeled using a three-pore kinetic model is illustrated.
- the three-pore kinetic model again used drain times selected from drain volume and drain flowrate profiles, similar to FIGS. 3 and 4 , calculated via the equation above.
- the patient instead of four exchanges of two liter fills each, the patient undergoes a first exchange using a two liter fill, and then four exchanges each of a 1.5 liter fill, totaling eight liters like above. PET characteristic is again high.
- FIG. 8B A modeled drain time and corresponding drain volume is shown for each cycle in FIG. 8B .
- the drain volume met the MDP requirement of 85% and the minimum drain flowrate met the FRT requirement of 75 ml/min shown in FIG. 8A .
- FIG. 8A also shows patient specific parameters of an FTP of 65% and a Q max of 80 ml/min.
- the drain time and drain volume vary from cycle to cycle because initial drain volume V D0 varies from cycle to cycle.
- the first drain volume is the biggest and the first drain time is the longest because the first fill is the biggest, namely, two liters versus 1.5 liters for the remaining four fills.
- the drain volumes and drain times increase from cycle two to cycle five because residual volume increases in each instance from cycle two to cycle five.
- FIGS. 8B and 9 highlight that five exchange or cycle therapy of FIG. 8B predicts a reduction of the maximum peak volume to roughly 2350 ml, which may be better suited for the particular patient.
- FIG. 8C shows the three-pore kinetic model's predicted UF removed for the therapy of FIG. 8B .
- the UF removed and overall clearances are comparable to those of FIG. 6C , and the patient absorbs less glucose, which is beneficial because the patient does not gain as much weight.
- the therapy of FIG. 8B may be more desirable than the therapy of FIG. 6B .
- the more accurately predicted drain times and volumes discussed herein allow the therapies of FIGS. 6B and 8B to be predicted more accurately, so that a better and more informed decision can be made for the patient.
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- External Artificial Organs (AREA)
Abstract
Description
- The present disclosure relates to medical fluid delivery and in particular to peritoneal dialysis fluid delivery.
- Due to disease or other causes, a person's renal system can fail. In renal failure of any cause, there are several physiological derangements. The balance of water, minerals and the excretion of daily metabolic load is no longer possible in renal failure. During renal failure, toxic end products of nitrogen metabolism (urea, creatinine, uric acid, and others) can accumulate in blood and tissues.
- Kidney failure and reduced kidney function have been treated with dialysis. Dialysis removes waste, toxins and excess water from the body that would otherwise have been removed by normal functioning kidneys. Dialysis treatment for replacement of kidney functions is critical to many people because the treatment is life saving. One who has failed kidneys could not continue to live without replacing at least the filtration functions of the kidneys.
- One type of dialysis is peritoneal dialysis. Peritoneal dialysis uses a dialysis solution or “dialysate”, which is infused into a patient's peritoneal cavity through a catheter implanted in the cavity. The dialysate contacts the patient's peritoneal membrane in the peritoneal cavity. Waste, toxins and excess water pass from the patient's bloodstream through the peritoneal membrane and into the dialysate. The transfer of waste, toxins, and water from the bloodstream into the dialysate occurs due to diffusion and osmosis, i.e., an osmotic gradient occurs across the membrane. The spent dialysate drains from the patient's peritoneal cavity and removes the waste, toxins and excess water from the patient. This cycle is repeated.
- There are various types of peritoneal dialysis therapies, including continuous ambulatory peritoneal dialysis (“CAPD”) and automated peritoneal dialysis (“APD”). CAPD is a manual dialysis treatment, in which the patient connects an implanted catheter to a drain and allows a spent dialysate fluid to drain from the patient's peritoneal cavity. The patient then connects the catheter to a bag of fresh dialysate and manually infuses fresh dialysate through the catheter and into the patient's peritoneal cavity. The patient disconnects the catheter from the fresh dialysate bag and allows the dialysate to dwell within the cavity to transfer waste, toxins and excess water from the patient's bloodstream to the dialysate solution. After a dwell period, the patient repeats the manual dialysis procedure.
- In CAPD the patient performs several drain, fill, and dwell cycles during the day, for example, about four times per day. Each treatment cycle typically takes about four to five hours. APD is similar to CAPD in that the dialysis treatment includes a drain, fill, and dwell cycle. APD machines, however, perform four to five cycles of peritoneal dialysis treatment automatically, typically overnight while the patient sleeps. Like CAPD, APD machines connect fluidly to an implanted catheter, to one or more sources or bags of fresh dialysate and to a fluid drain.
- The APD machines pump fresh dialysate from the dialysate source, through the catheter, into the patient's peritoneal cavity and allow the dialysate to dwell within the cavity so that the transfer of waste, toxins and excess water from the patient's bloodstream to the dialysate solution can take place. The APD machines then pump spent dialysate from the peritoneal cavity, though the catheter, to the drain. APD machines are typically computer controlled so that the dialysis treatment occurs automatically when the patient is connected to the dialysis machine, for example, when the patient sleeps. That is, the APD systems automatically and sequentially pump fluid into the peritoneal cavity, allow for a dwell, pump fluid out of the peritoneal cavity and repeat the procedure. As with the manual process, several drain, fill, and dwell cycles will occur during APD. A “last fill” is typically used at the end of APD, which remains in the peritoneal cavity of the patient when the patient disconnects from the dialysis machine for the day.
- In both CAPD and APD, the therapy must allow for a certain amount of time for the patient drain phase. It is important that the drain phase be sufficiently long to allow the patient to drain as completely as possible. On the other hand, if too much time is allowed for the drain phase, that is, the patient is basically finished draining too far in advance of the end of the drain phase, then the drain phase is extending needlessly into time that the patient could be filling or is appending the last fill's dwell phase needlessly. A need accordingly exists for a way to predict and optimize drain phase time to allow for the patient to drain completely or as much as is reasonably possible without needlessly extending drain time and wasting time that could be used to increase therapy dwell.
- The present disclosure sets forth a method and apparatus for predicting a patient's optimal drain phase time. The optimal drain phase time is useful for at least two purposes. First, the optimal drain phase time can be implemented into the patient's continuous ambulatory peritoneal dialysis (“CAPD”) or automated peritoneal dialysis (“APD”) treatment. Second, the optimal drain phase time can be used in the further modeling of possible treatments or therapy regimes for the patient, one or more desirable ones of which can then be selected for actual use. The further treatment or prescription modeling can be done using a three-pore model as discussed below.
- The drain phase modeling attempts to match the patient's actual drain profile given certain inputs. One important patient specific input is maximum drain flowrate or Qmax. Qmax typically occurs at the start of the drain. Some patients will drain more quickly than others due to patient-specific physical characteristics. Also, the position of the patient affects Qmax. A patient standing or sitting may drain quicker than if the same patient is lying down in a supine or prone position. Qmax is determined in one embodiment by experimentation with the patient in a drain position that the patient expects to be for at least most treatments.
- Referring now to the drawings and in particular to
FIGS. 1 and 2 , typical drain volume and corresponding flowrate profiles, respectively, are shown. The profiles were derived in a study by Brandes J. C., Packard, J. W., Watters S. K., Fritsche C., Optimization of Dialysate Flow and Mass Transfer During Automated Peritoneal Dialysis, American Journal of Kidney Diseases, Vol. 25, No. 4 (April), 1995, pp. 603-610.FIG. 1 shows a constant drop in drain volume from a full volume of about 2000 ml to a transition drain volume of about 350 to 400 ml. This constant drop occurs while flowrate is generally at a maximum, e.g., Qmax, which is about 350 ml/min as seen inFIG. 2 . Below the transition volume, the volume drains according to a decaying exponential curve. Drain flowrate after the transition point also slows to zero according to a similar curve. The transition point in bothFIGS. 1 and 2 separates a first segment from a second segment as discussed in detail below. - According to the present method and apparatus, an equation has been formed that models the first and second segments. The equation relies principally on Qmax for the first segment. The equation employs a switching component Φ that either (i) switches the first segment portion of the equation on and the second segment portion of the equation off or (ii) switches the first segment portion of the equation off and the second segment portion of the equation on. The transition time (or volume) at which switching component Φ switches from 1 to 0 is determined empirically, e.g., the duration of the constant high flow Qmax can be measured for each individual patient, and for a particular drain position. The second segment portion of the equation also employs an exponential drain rate constant α, which is patient specific and is determined empirically. The equation relies principally on a for the second segment.
- The drain modeling equation can be used in a number of ways. First, it can be used to form individual settings for flowrate threshold (“FRT”) and/or minimum drain volume (“MDV”). One or both of FRT and MDV may be set as alarm limits in an automated peritoneal dialysis (“APD”) machine (which can use either gravity draining or pumped draining).
- Second, the drain modeling equation can be used to more accurately model a patient's reaction to therapy, e.g., via a three-pore model. For example, the three-pore model uses a drain time (or dwell time, which is a function of drain time) in one or more places to model a particular patient's reaction to a particular therapy prescription.
- Third, the drain modeling equation can be used to set drain and dwell times or periods for actual operation of an APD machine, for example, performing a multiple exchange therapy. Again, the machine can be a gravity drain machine or drain via a pump.
- Fourth, the drain modeling equation can be used to set drain times or periods for patients performing manual peritoneal dialysis or CAPD.
- It is accordingly an advantage of the present disclosure to provide a method and apparatus that attempt to optimize a drain phase in peritoneal dialysis.
- It is another advantage of the present disclosure to provide a method and apparatus that attempt to minimize drain time.
- It is a further advantage of the present disclosure to provide a method and apparatus that attempt to maximize drain volume.
- It is yet another advantage of the present disclosure to provide a method and apparatus that attempt to prevent patient overfill.
- It is yet a further advantage of the present disclosure to provide a method and apparatus that attempt to prevent low drain flowrate alarms.
- It is still another advantage of the present disclosure to provide a method and apparatus that attempt to improve estimation of therapy outcome parameters such as UF, urea clearance and creatinine clearance.
- Additional features and advantages are described herein, and will be apparent from the following Detailed Description and the figures.
-
FIGS. 1 and 2 are drain volume and drain phase flowrate profiles derived from actual patient data via a study. -
FIGS. 3 and 4 are drain volume and drain phase flowrate profiles derived via the modeling method and apparatus of the present disclosure. -
FIG. 5 is a schematic diagram illustrating how the drain volume modeling method and apparatus of the present disclosure is used with kinetic modeling of patient therapy outcomes, e.g., using a three-pore model. -
FIGS. 6A to 6C illustrate a first therapy modeled via kinetic model using information obtained from the drain volume modeling method and apparatus of the present disclosure. -
FIG. 7 is a graph illustrating peritoneal volume over time for the therapy illustrated inFIGS. 6A to 6C . -
FIGS. 8A to 8C illustrate a second therapy modeled via kinetic model using information obtained from the drain volume modeling method and apparatus of the present disclosure. -
FIG. 9 is a graph illustrating peritoneal volume over time for the therapy illustrated inFIGS. 8A to 8C . - The drain volume modeling method and apparatus of the present disclosure uses the concepts and terminology described below.
- Maximum drain flowrate, Qmax, is the initial drain flowrate, which should be a maximum flowrate of the drain flowrate profile. The present disclosure applies to different kinds of APD machines. For example, the APD machine can use a gravity fill and drain, in which the supply bag is placed elevationally above the patient and the drain bag is placed elevationally below the patient. For such a machine, Qmax is determined empirically as discussed below. Qmax is also determined empirically for continuous ambulatory peritoneal dialysis (“CAPD”), which also uses gravity for filling and draining. The HomeChoice® machine, made by the assignee of the present disclosure, pumps spent fluid from the patient to drain. Here, Qmax is set by the pump speed, does not need to be determined empirically, and is independent of the patient's drain position.
- For modeling purposes, Qmax is assumed to remain constant until the patient drain transitions to an exponential decay portion or segment of the profile. Qmax is patient specific and is also patient drain position specific. Qmax is determined empirically by, for example, weighing the patient's drain over time for a number of exchanges and then averaging the resulting rate. Qmax may vary for a patient depending upon whether the patient is sitting, laying down or standing during drain. It is contemplated therefore to obtain empirical data for Qmax while the patient is positioned for drain in a position that the patient intends to be for most or all drains. It is also contemplated to obtain empirical data for Qmax while the patient is in different positions for drain, e.g., one set of data while the patient is standing for drain, one set of data while the patient is sitting for drain, and a third set of data while the patient is laying down for drain. In such case, an automated peritoneal dialysis (“APD”) machine can be programmed to ask the patient which drain position the patient intends to use for the current treatment.
- Flow transition percent (“FTP”) is the percentage of the peritoneal volume at which the patient drain transitions from the first segment, having constant drain flowrate Qmax, to the second segment having the decaying exponential flowrate. FTP sets the volume (or percentage of total time) at which switching component Φ, discussed in detail herein, switches from 1 to 0. FTP is patient specific and is determined empirically regardless of the type of APD machine (gravity drain or pump to drain) used. FTP may also be dependent upon patient drain position for gravity fed systems or treatments.
- The second drain profile segment, having the decaying exponential flowrate, is controlled in large part by a decaying exponential constant α, which is also patient specific and is determined empirically regardless of the type of APD machine (gravity drain or pump to drain) used or if CAPD is performed instead. α itself may depend on drain type, pump or gravity, and perhaps pump type, e.g., peristaltic versus membrane. α may also be dependent upon patient drain position for gravity fed systems or treatments. α is determined by obtaining multiple data points (volume for a given time and flowrate for a given time) during the second or decaying exponential drain flow and volume segment. Different “potential” values of a are then plugged into the second segment of the drain model shown below until a value of α that outputs correct volume and correct flowrate values for the corresponding points in time, or which best match the measured data, is obtained. α can for example be in a range of 0.1 to 0.15.
- One parameter that may be set in the software of an APD machine for alarm purposes is a minimum drain percentage (“MDP”). MDP sets a drain limit above which the patient's drain volume must reach during the drain phase. If, for example, the patient does not drain at least eighty percent of the total spent volume in the patient's peritoneum, The APD will sound an alarm and therapy may be halted, preventing the machine from advancing to the next fill phase until the low drain is addressed. As discussed below, MDP can be used with the modeled drain profiles to determine an appropriate dwell time for the patient, in particular, it sets a minimum dwell time to reach MDP
- Flowrate threshold (“FRT”) may also be set in the software of an APD machine for alarm purposes. FRT sets a minimum drain flowrate level below which the machine may alarm, for example, indicating that the drain flowrate is so low that the treatment in essence is wasting time by continuing drain. FRT can alternatively be set to define a drain flow limit below which the drain is stopped. As discussed below, FTP and MDP can be used, alone or in combination, with the modeled drain profiles to determine an appropriate dwell time for the patient, which ensures that the dwell time is long enough for MDP to be met but does not continue long enough for the drain flowrate to fall below FTP.
- Referring now to
FIGS. 3 and 4 , drain volume and drain flowrate profiles are shown, respectively, which have been modeled to attempt to match the actual drain volume and drain flowrate profiles ofFIGS. 1 and 2 . The drain volume profile ofFIG. 3 is obtained via the following equation or algorithm: -
V D =[V D0 −Q max *t]*Φ+[V D0 *e −αt]*(1−Φ), wherein - VD is an instantaneous remaining drain volume in the patient at time t
- VD0 is an initial patient drain volume (fill volume plus UF accumulated over previous dwell);
- Qmax discussed above is a starting flowrate and is assumed to be constant;
- Φ discussed above is a switching component (from 1 to 0 at FTP), which is based on time or volume;
- α discussed above is a decaying exponential constant; and
- t is time.
- The modeled flowrate profile of
FIG. 4 is determined by dividing a change in volume by a corresponding change in time, e.g., drop from 2300 ml to 2600 ml over first two minutes leading to flowrate over that period of 350 m/min. Specific flowrate values can be obtained via a derivative dV/dT, especially in the second, non-linear, segment. - The equation above and resulting profiles of
FIGS. 3 and 4 show a first segment that is dependent on VD0 and Qmax. VD0 is the previous fill volume plus an amount of ultrafiltrate (“UF”) removed from the patient over the last dwell. The amount of UF can be estimated via a three-pore model given certain parameters, such as patient physiological characteristics (ability to remove UF), dextrose level of dialysate used and dwell time. For example, if the patient fill is 2000 ml of fresh dialysate and it is determined from a patient kinetic model, such as a three-pore model, or perhaps experimentally, that the patient will acquire 300 ml of ultrafiltrate over the course of a known dwell period, VD0 will be set to 2300 ml. Qmax is determined empirically or set via pump speed. - The equation above and resulting profiles of
FIGS. 3 and 4 show a second segment that is dependent on VD0 and α. α is determined empirically as discussed above. The transition point in the above equation occurs when Φ switches from 1 to 0, which is determined empirically. The corresponding transition point in the profiles ofFIGS. 3 and 4 occurs when the straight line transitions to the curved or exponentially decaying line. - Referring now to
FIG. 5 , a schematic showing fill, dwell and drain phases of a peritoneal dialysis treatment illustrates how the drain volume modeling method and apparatus of the present disclosure interfaces with the kinetic modeling of patient therapy outcomes, e.g., using a three-pore model. The duration of the fill phase in APD is set via a pump speed. The duration of the fill phase in CAPD is determined principally by head height of the fill bag above the patient. - Dwell phase duration and drain phase duration are related. A treatment typically requires multiple, e.g., four, fills that are made over an entire treatment, e.g., eight hours. The set fill times leave only so much time for the dwell and drain phases. The less time needed for drain, the more time left for dwell, which is desirable from both clearance and UF standpoints.
- Further, accurately modeling an adequate (MDP satisfied) but efficient (FTP satisfied) allows the dwell phase times to be determined accurately given the set fill times. The dwell phase times are important to the kinetic modeling as seen in
FIG. 5 . Thus, determining accurate dwell times allows the kinetic modeling of patient results to different therapy prescriptions to be done more accurately. One suitable modified three-pore kinetic model is described in Rippe B., Sterlin G., and Haraldsson B., Computer Simulations of Peritoneal Fluid Transport in CAPD, Kidney Int. 1991; 40: 315 to 325. Another suitable modified three-pore kinetic model is described in Vonesh E. F. and Rippe B., Net Fluid Adsorption Under Membrane Transport Models of Peritoneal Dialysis, Blood Purif. 1992; 10: 209 to 226, the entire contents of each of which are incorporated herein by reference and relied upon. - Referring now to
FIGS. 6A to 6C , one example therapy modeled using a three-pore kinetic model is illustrated. The three-pore kinetic model used drain times selected from drain volume and drain flowrate profiles, similar toFIGS. 3 and 4 , which were determined via the equation above. Here, the patient undergoes four exchanges of two liter fills each, totaling eight liters. PET characteristic is H or high meaning the patient in general has high toxin and glucose clearances. - A modeled drain time and corresponding drain volume is shown for each cycle in
FIG. 6B . In each case, the drain volume met the MDP requirement of 85%, and the minimum drain flowrate met the FRT requirement of 75 ml/min, both of which are shown inFIG. 6A .FIG. 6A also shows patient specific parameters, namely, an FTP of 75% (percentage of drain after which switching component Φ changes from 1 to 0) and a Qmax of 80 ml/min. - As seen in
FIG. 6B , the drain time and drain volume selected vary from cycle to cycle because initial drain volume VD0 varies from cycle to cycle. Initial drain volume VD0 varies from cycle to cycle because residual volume (volume remaining in the patient's peritoneum after drain is completed) varies from cycle to cycle. As seen inFIG. 6B , residual volume jumps from 150 ml aftercycle 1 to 537 ml forcycle 2 and then increases more slowly to 631 ml and 654 ml for cycles three and four. -
FIG. 6C shows the three-pore kinetic model's predicted UF removed for the therapy ofFIG. 6B .FIG. 6B andFIG. 7 (graphing peak volume over the cycles) highlight one concern about the “four exchange each of a two liter fill” therapy ofFIG. 6B , namely, that the predicted peak volume of the patient indicates the patient may become overfilled. A peak volume of roughly 2700 ml may be too high for many patients. - Referring now to
FIGS. 8A to 8C , a second example therapy modeled using a three-pore kinetic model is illustrated. The three-pore kinetic model again used drain times selected from drain volume and drain flowrate profiles, similar toFIGS. 3 and 4 , calculated via the equation above. Here, instead of four exchanges of two liter fills each, the patient undergoes a first exchange using a two liter fill, and then four exchanges each of a 1.5 liter fill, totaling eight liters like above. PET characteristic is again high. - A modeled drain time and corresponding drain volume is shown for each cycle in
FIG. 8B . In each case, the drain volume met the MDP requirement of 85% and the minimum drain flowrate met the FRT requirement of 75 ml/min shown inFIG. 8A .FIG. 8A also shows patient specific parameters of an FTP of 65% and a Qmax of 80 ml/min. As seen inFIG. 8B , the drain time and drain volume vary from cycle to cycle because initial drain volume VD0 varies from cycle to cycle. Here, the first drain volume is the biggest and the first drain time is the longest because the first fill is the biggest, namely, two liters versus 1.5 liters for the remaining four fills. The drain volumes and drain times increase from cycle two to cycle five because residual volume increases in each instance from cycle two to cycle five. -
FIGS. 8B and 9 highlight that five exchange or cycle therapy ofFIG. 8B predicts a reduction of the maximum peak volume to roughly 2350 ml, which may be better suited for the particular patient.FIG. 8C shows the three-pore kinetic model's predicted UF removed for the therapy ofFIG. 8B . The UF removed and overall clearances are comparable to those ofFIG. 6C , and the patient absorbs less glucose, which is beneficial because the patient does not gain as much weight. Thus, assuming that the additional exchange can be done in a prescribed or desired total therapy duration, the therapy ofFIG. 8B may be more desirable than the therapy ofFIG. 6B . In any case, the more accurately predicted drain times and volumes discussed herein allow the therapies ofFIGS. 6B and 8B to be predicted more accurately, so that a better and more informed decision can be made for the patient. - It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present subject matter and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
Claims (20)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/389,886 US8521482B2 (en) | 2009-02-20 | 2009-02-20 | Simulation of patient drain phase in peritoneal dialysis |
PCT/US2010/024745 WO2010096659A1 (en) | 2009-02-20 | 2010-02-19 | Simulation of patient drain phase in peritoneal dialysis |
EP10705073A EP2398529B1 (en) | 2009-02-20 | 2010-02-19 | Simulation of patient drain phase in peritoneal dialysis |
US13/954,427 US20130317795A1 (en) | 2009-02-20 | 2013-07-30 | Simulation of patient drain phase in peritoneal dialysis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/389,886 US8521482B2 (en) | 2009-02-20 | 2009-02-20 | Simulation of patient drain phase in peritoneal dialysis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/954,427 Continuation US20130317795A1 (en) | 2009-02-20 | 2013-07-30 | Simulation of patient drain phase in peritoneal dialysis |
Publications (2)
Publication Number | Publication Date |
---|---|
US20100217180A1 true US20100217180A1 (en) | 2010-08-26 |
US8521482B2 US8521482B2 (en) | 2013-08-27 |
Family
ID=42115835
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/389,886 Active 2032-06-29 US8521482B2 (en) | 2009-02-20 | 2009-02-20 | Simulation of patient drain phase in peritoneal dialysis |
US13/954,427 Abandoned US20130317795A1 (en) | 2009-02-20 | 2013-07-30 | Simulation of patient drain phase in peritoneal dialysis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/954,427 Abandoned US20130317795A1 (en) | 2009-02-20 | 2013-07-30 | Simulation of patient drain phase in peritoneal dialysis |
Country Status (3)
Country | Link |
---|---|
US (2) | US8521482B2 (en) |
EP (1) | EP2398529B1 (en) |
WO (1) | WO2010096659A1 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013091814A3 (en) * | 2011-12-20 | 2013-10-10 | Fresenius Medical Care Deutschland Gmbh | Method and device for preparing medical treatment devices |
US8926542B2 (en) | 2011-04-29 | 2015-01-06 | Medtronic, Inc. | Monitoring fluid volume for patients with renal disease |
US9713665B2 (en) | 2014-12-10 | 2017-07-25 | Medtronic, Inc. | Degassing system for dialysis |
US9827361B2 (en) | 2013-02-02 | 2017-11-28 | Medtronic, Inc. | pH buffer measurement system for hemodialysis systems |
US9861733B2 (en) | 2012-03-23 | 2018-01-09 | Nxstage Medical Inc. | Peritoneal dialysis systems, devices, and methods |
US9872949B2 (en) | 2013-02-01 | 2018-01-23 | Medtronic, Inc. | Systems and methods for multifunctional volumetric fluid control |
US9895479B2 (en) | 2014-12-10 | 2018-02-20 | Medtronic, Inc. | Water management system for use in dialysis |
US9907897B2 (en) | 2011-03-23 | 2018-03-06 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US9943633B2 (en) | 2009-09-30 | 2018-04-17 | Medtronic Inc. | System and method to regulate ultrafiltration |
US10010663B2 (en) | 2013-02-01 | 2018-07-03 | Medtronic, Inc. | Fluid circuit for delivery of renal replacement therapies |
US10076283B2 (en) | 2013-11-04 | 2018-09-18 | Medtronic, Inc. | Method and device to manage fluid volumes in the body |
US10098993B2 (en) | 2014-12-10 | 2018-10-16 | Medtronic, Inc. | Sensing and storage system for fluid balance |
DE102017110607A1 (en) * | 2017-05-16 | 2018-11-22 | Fresenius Medical Care Deutschland Gmbh | peritoneal dialysis |
US10543052B2 (en) | 2013-02-01 | 2020-01-28 | Medtronic, Inc. | Portable dialysis cabinet |
US10695481B2 (en) | 2011-08-02 | 2020-06-30 | Medtronic, Inc. | Hemodialysis system having a flow path with a controlled compliant volume |
US10850016B2 (en) | 2013-02-01 | 2020-12-01 | Medtronic, Inc. | Modular fluid therapy system having jumpered flow paths and systems and methods for cleaning and disinfection |
US10857277B2 (en) | 2011-08-16 | 2020-12-08 | Medtronic, Inc. | Modular hemodialysis system |
US10874787B2 (en) | 2014-12-10 | 2020-12-29 | Medtronic, Inc. | Degassing system for dialysis |
US10905816B2 (en) | 2012-12-10 | 2021-02-02 | Medtronic, Inc. | Sodium management system for hemodialysis |
US10994064B2 (en) | 2016-08-10 | 2021-05-04 | Medtronic, Inc. | Peritoneal dialysate flow path sensing |
US11013843B2 (en) | 2016-09-09 | 2021-05-25 | Medtronic, Inc. | Peritoneal dialysis fluid testing system |
US11033667B2 (en) | 2018-02-02 | 2021-06-15 | Medtronic, Inc. | Sorbent manifold for a dialysis system |
US11110215B2 (en) | 2018-02-23 | 2021-09-07 | Medtronic, Inc. | Degasser and vent manifolds for dialysis |
US20210379259A1 (en) * | 2020-06-04 | 2021-12-09 | Fresenius Medical Care Holdings, Inc. | Administering dialysis treatment using a hybrid automated peritoneal dialysis system |
US11207454B2 (en) | 2018-02-28 | 2021-12-28 | Nxstage Medical, Inc. | Fluid preparation and treatment devices methods and systems |
US11278654B2 (en) | 2017-12-07 | 2022-03-22 | Medtronic, Inc. | Pneumatic manifold for a dialysis system |
US11806457B2 (en) | 2018-11-16 | 2023-11-07 | Mozarc Medical Us Llc | Peritoneal dialysis adequacy meaurements |
US11806456B2 (en) | 2018-12-10 | 2023-11-07 | Mozarc Medical Us Llc | Precision peritoneal dialysis therapy based on dialysis adequacy measurements |
US11850344B2 (en) | 2021-08-11 | 2023-12-26 | Mozarc Medical Us Llc | Gas bubble sensor |
US11883576B2 (en) | 2016-08-10 | 2024-01-30 | Mozarc Medical Us Llc | Peritoneal dialysis intracycle osmotic agent adjustment |
US11944733B2 (en) | 2021-11-18 | 2024-04-02 | Mozarc Medical Us Llc | Sodium and bicarbonate control |
US11965763B2 (en) | 2021-11-12 | 2024-04-23 | Mozarc Medical Us Llc | Determining fluid flow across rotary pump |
US12048791B2 (en) | 2017-06-24 | 2024-07-30 | Nxstage Medical, Inc. | Peritoneal dialysis fluid preparation and/or treatment devices methods and systems |
US12154673B2 (en) | 2021-08-02 | 2024-11-26 | Mozarc Medical Us Llc | Artificial intelligence assisted home therapy settings for dialysis |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8936720B2 (en) * | 2010-09-17 | 2015-01-20 | Baxter International Inc. | Drain and fill logic for automated peritoneal dialysis |
DE102014013229A1 (en) * | 2014-09-05 | 2016-03-10 | Fresenius Medical Care Deutschland Gmbh | Apparatus for performing a tidal peritoneal dialysis treatment |
US12128165B2 (en) | 2020-04-27 | 2024-10-29 | Mozarc Medical Us Llc | Dual stage degasser |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5334139A (en) * | 1991-02-18 | 1994-08-02 | Gambro Ab | Method of peritoneal dialysis using a tube set |
US5643201A (en) * | 1984-07-09 | 1997-07-01 | Peabody; Alan M. | Continuous peritoneal dialysis apparatus |
US5670057A (en) * | 1995-04-28 | 1997-09-23 | Baxter International Inc. | Apparatus and method for automatically performing peritoneal equilibration tests |
US6074359A (en) * | 1994-04-06 | 2000-06-13 | Baxter International Inc. | Method and apparatus for a tidal oscillating pulse peritoneal dialysis |
US6558334B2 (en) * | 2000-10-19 | 2003-05-06 | Florence Medical Ltd. | Apparatus for diagnosing lesion severity, and method therefor |
US6558343B1 (en) * | 1998-04-02 | 2003-05-06 | Debiotech S.A. | Device for peritoneal dialysis and method for using said device |
US6592542B2 (en) * | 2000-02-10 | 2003-07-15 | Baxter International Inc. | Method and apparatus for monitoring and controlling peritoneal dialysis therapy |
US6976973B1 (en) * | 2000-10-12 | 2005-12-20 | Baxter International Inc. | Peritoneal dialysis catheters |
US7238164B2 (en) * | 2002-07-19 | 2007-07-03 | Baxter International Inc. | Systems, methods and apparatuses for pumping cassette-based therapies |
US20080161751A1 (en) * | 2006-12-29 | 2008-07-03 | Plahey Kulwinder S | Peritoneal dialysis therapy validation |
US20090271119A1 (en) * | 2005-10-18 | 2009-10-29 | Hiroyuki Hamada | Pertioneal Membrane Function Test Method, Peritoneal Membrane Function Test Apparatus and Peritoneal Membrane Function Test Program |
US20100010427A1 (en) * | 2008-07-09 | 2010-01-14 | Baxter International Inc. | Dialysis system having trending and alert generation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1017434A4 (en) * | 1996-10-22 | 2000-08-30 | Renal Solutions Inc | Continuous flow-through peritoneal dialysis (cfpd) method with control of intraperitoneal pressure |
US6814547B2 (en) * | 2002-05-24 | 2004-11-09 | Baxter International Inc. | Medical fluid pump |
PL1691863T3 (en) | 2003-10-13 | 2008-07-31 | Fresenius Medical Care Deutschland Gmbh | A device for carrying out a peritoneal dialysis treatment |
-
2009
- 2009-02-20 US US12/389,886 patent/US8521482B2/en active Active
-
2010
- 2010-02-19 EP EP10705073A patent/EP2398529B1/en active Active
- 2010-02-19 WO PCT/US2010/024745 patent/WO2010096659A1/en active Application Filing
-
2013
- 2013-07-30 US US13/954,427 patent/US20130317795A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643201A (en) * | 1984-07-09 | 1997-07-01 | Peabody; Alan M. | Continuous peritoneal dialysis apparatus |
US5334139A (en) * | 1991-02-18 | 1994-08-02 | Gambro Ab | Method of peritoneal dialysis using a tube set |
US6074359A (en) * | 1994-04-06 | 2000-06-13 | Baxter International Inc. | Method and apparatus for a tidal oscillating pulse peritoneal dialysis |
US5670057A (en) * | 1995-04-28 | 1997-09-23 | Baxter International Inc. | Apparatus and method for automatically performing peritoneal equilibration tests |
US6558343B1 (en) * | 1998-04-02 | 2003-05-06 | Debiotech S.A. | Device for peritoneal dialysis and method for using said device |
US6592542B2 (en) * | 2000-02-10 | 2003-07-15 | Baxter International Inc. | Method and apparatus for monitoring and controlling peritoneal dialysis therapy |
US6976973B1 (en) * | 2000-10-12 | 2005-12-20 | Baxter International Inc. | Peritoneal dialysis catheters |
US6558334B2 (en) * | 2000-10-19 | 2003-05-06 | Florence Medical Ltd. | Apparatus for diagnosing lesion severity, and method therefor |
US7238164B2 (en) * | 2002-07-19 | 2007-07-03 | Baxter International Inc. | Systems, methods and apparatuses for pumping cassette-based therapies |
US20090271119A1 (en) * | 2005-10-18 | 2009-10-29 | Hiroyuki Hamada | Pertioneal Membrane Function Test Method, Peritoneal Membrane Function Test Apparatus and Peritoneal Membrane Function Test Program |
US20080161751A1 (en) * | 2006-12-29 | 2008-07-03 | Plahey Kulwinder S | Peritoneal dialysis therapy validation |
US20100010427A1 (en) * | 2008-07-09 | 2010-01-14 | Baxter International Inc. | Dialysis system having trending and alert generation |
Non-Patent Citations (1)
Title |
---|
M. Misra, K.D. Nolph, "Adequacy in dialysis: intermittent versus continuous therapies" NEFROLOGIA. Vol. XX. Suplemento 3. 2000, pages 25-32. * |
Cited By (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9943633B2 (en) | 2009-09-30 | 2018-04-17 | Medtronic Inc. | System and method to regulate ultrafiltration |
US11224684B2 (en) | 2011-03-23 | 2022-01-18 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10610630B2 (en) | 2011-03-23 | 2020-04-07 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10603424B2 (en) | 2011-03-23 | 2020-03-31 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10688234B2 (en) | 2011-03-23 | 2020-06-23 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10688235B2 (en) | 2011-03-23 | 2020-06-23 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10046100B2 (en) | 2011-03-23 | 2018-08-14 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US11717601B2 (en) | 2011-03-23 | 2023-08-08 | Nxstage Medical, Inc. | Dialysis systems, devices, and methods |
US11690941B2 (en) | 2011-03-23 | 2023-07-04 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US11433169B2 (en) | 2011-03-23 | 2022-09-06 | Nxstage Medical, Inc. | Dialysis systems, devices, and methods |
US11433170B2 (en) | 2011-03-23 | 2022-09-06 | Nxstage Medical, Inc. | Dialysis systems, devices, and methods |
US9907897B2 (en) | 2011-03-23 | 2018-03-06 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10898630B2 (en) | 2011-03-23 | 2021-01-26 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US11135348B2 (en) | 2011-03-23 | 2021-10-05 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
US10406268B2 (en) | 2011-04-29 | 2019-09-10 | Medtronic, Inc. | Blood fluid removal system performance monitoring |
US9750862B2 (en) | 2011-04-29 | 2017-09-05 | Medtronic, Inc. | Adaptive system for blood fluid removal |
US10064985B2 (en) | 2011-04-29 | 2018-09-04 | Medtronic, Inc. | Precision blood fluid removal therapy based on patient monitoring |
US9642960B2 (en) | 2011-04-29 | 2017-05-09 | Medtronic, Inc. | Monitoring fluid volume for patients with renal disease |
US10967112B2 (en) | 2011-04-29 | 2021-04-06 | Medtronic, Inc. | Adaptive system for blood fluid removal |
US8951219B2 (en) | 2011-04-29 | 2015-02-10 | Medtronic, Inc. | Fluid volume monitoring for patients with renal disease |
US10293092B2 (en) | 2011-04-29 | 2019-05-21 | Medtronic, Inc. | Electrolyte and pH monitoring for fluid removal processes |
US9968721B2 (en) | 2011-04-29 | 2018-05-15 | Medtronic, Inc. | Monitoring fluid volume for patients with renal disease |
US9700661B2 (en) | 2011-04-29 | 2017-07-11 | Medtronic, Inc. | Chronic pH or electrolyte monitoring |
US10179198B2 (en) | 2011-04-29 | 2019-01-15 | Medtronic, Inc. | Electrolyte and pH monitoring for fluid removal processes |
US8926542B2 (en) | 2011-04-29 | 2015-01-06 | Medtronic, Inc. | Monitoring fluid volume for patients with renal disease |
US11759557B2 (en) | 2011-04-29 | 2023-09-19 | Mozarc Medical Us Llc | Adaptive system for blood fluid removal |
US10695481B2 (en) | 2011-08-02 | 2020-06-30 | Medtronic, Inc. | Hemodialysis system having a flow path with a controlled compliant volume |
US10722636B2 (en) | 2011-08-02 | 2020-07-28 | Medtronic, Inc. | Hemodialysis system having a flow path with a controlled compliant volume |
US10857277B2 (en) | 2011-08-16 | 2020-12-08 | Medtronic, Inc. | Modular hemodialysis system |
WO2013091814A3 (en) * | 2011-12-20 | 2013-10-10 | Fresenius Medical Care Deutschland Gmbh | Method and device for preparing medical treatment devices |
US9861733B2 (en) | 2012-03-23 | 2018-01-09 | Nxstage Medical Inc. | Peritoneal dialysis systems, devices, and methods |
US10905816B2 (en) | 2012-12-10 | 2021-02-02 | Medtronic, Inc. | Sodium management system for hemodialysis |
US11786645B2 (en) | 2013-02-01 | 2023-10-17 | Mozarc Medical Us Llc | Fluid circuit for delivery of renal replacement therapies |
US10010663B2 (en) | 2013-02-01 | 2018-07-03 | Medtronic, Inc. | Fluid circuit for delivery of renal replacement therapies |
US10850016B2 (en) | 2013-02-01 | 2020-12-01 | Medtronic, Inc. | Modular fluid therapy system having jumpered flow paths and systems and methods for cleaning and disinfection |
US10543052B2 (en) | 2013-02-01 | 2020-01-28 | Medtronic, Inc. | Portable dialysis cabinet |
US9872949B2 (en) | 2013-02-01 | 2018-01-23 | Medtronic, Inc. | Systems and methods for multifunctional volumetric fluid control |
US10561776B2 (en) | 2013-02-01 | 2020-02-18 | Medtronic, Inc. | Fluid circuit for delivery of renal replacement therapies |
US10532141B2 (en) | 2013-02-01 | 2020-01-14 | Medtronic, Inc. | Systems and methods for multifunctional volumetric fluid control |
US9827361B2 (en) | 2013-02-02 | 2017-11-28 | Medtronic, Inc. | pH buffer measurement system for hemodialysis systems |
US11064894B2 (en) | 2013-11-04 | 2021-07-20 | Medtronic, Inc. | Method and device to manage fluid volumes in the body |
US10076283B2 (en) | 2013-11-04 | 2018-09-18 | Medtronic, Inc. | Method and device to manage fluid volumes in the body |
US9713665B2 (en) | 2014-12-10 | 2017-07-25 | Medtronic, Inc. | Degassing system for dialysis |
US10098993B2 (en) | 2014-12-10 | 2018-10-16 | Medtronic, Inc. | Sensing and storage system for fluid balance |
US10195327B2 (en) | 2014-12-10 | 2019-02-05 | Medtronic, Inc. | Sensing and storage system for fluid balance |
US9895479B2 (en) | 2014-12-10 | 2018-02-20 | Medtronic, Inc. | Water management system for use in dialysis |
US10874787B2 (en) | 2014-12-10 | 2020-12-29 | Medtronic, Inc. | Degassing system for dialysis |
US10420872B2 (en) | 2014-12-10 | 2019-09-24 | Medtronic, Inc. | Degassing system for dialysis |
US12194214B2 (en) | 2016-08-10 | 2025-01-14 | Mozarc Medical Us Llc | Peritoneal dialysate flow path sensing |
US11883576B2 (en) | 2016-08-10 | 2024-01-30 | Mozarc Medical Us Llc | Peritoneal dialysis intracycle osmotic agent adjustment |
US10994064B2 (en) | 2016-08-10 | 2021-05-04 | Medtronic, Inc. | Peritoneal dialysate flow path sensing |
US11013843B2 (en) | 2016-09-09 | 2021-05-25 | Medtronic, Inc. | Peritoneal dialysis fluid testing system |
US11679186B2 (en) | 2016-09-09 | 2023-06-20 | Mozarc Medical Us Llc | Peritoneal dialysis fluid testing system |
DE102017110607A1 (en) * | 2017-05-16 | 2018-11-22 | Fresenius Medical Care Deutschland Gmbh | peritoneal dialysis |
US12048791B2 (en) | 2017-06-24 | 2024-07-30 | Nxstage Medical, Inc. | Peritoneal dialysis fluid preparation and/or treatment devices methods and systems |
US11278654B2 (en) | 2017-12-07 | 2022-03-22 | Medtronic, Inc. | Pneumatic manifold for a dialysis system |
US11033667B2 (en) | 2018-02-02 | 2021-06-15 | Medtronic, Inc. | Sorbent manifold for a dialysis system |
US11110215B2 (en) | 2018-02-23 | 2021-09-07 | Medtronic, Inc. | Degasser and vent manifolds for dialysis |
US11872337B2 (en) | 2018-02-28 | 2024-01-16 | Nxstage Medical, Inc. | Fluid preparation and treatment devices methods and systems |
US11364328B2 (en) | 2018-02-28 | 2022-06-21 | Nxstage Medical, Inc. | Fluid preparation and treatment devices methods and systems |
US11207454B2 (en) | 2018-02-28 | 2021-12-28 | Nxstage Medical, Inc. | Fluid preparation and treatment devices methods and systems |
US11806457B2 (en) | 2018-11-16 | 2023-11-07 | Mozarc Medical Us Llc | Peritoneal dialysis adequacy meaurements |
US11806456B2 (en) | 2018-12-10 | 2023-11-07 | Mozarc Medical Us Llc | Precision peritoneal dialysis therapy based on dialysis adequacy measurements |
US20210379259A1 (en) * | 2020-06-04 | 2021-12-09 | Fresenius Medical Care Holdings, Inc. | Administering dialysis treatment using a hybrid automated peritoneal dialysis system |
US11717600B2 (en) * | 2020-06-04 | 2023-08-08 | Fresenius Medical Care Holdings, Inc. | Administering dialysis treatment using a hybrid automated peritoneal dialysis system |
US12154673B2 (en) | 2021-08-02 | 2024-11-26 | Mozarc Medical Us Llc | Artificial intelligence assisted home therapy settings for dialysis |
US11850344B2 (en) | 2021-08-11 | 2023-12-26 | Mozarc Medical Us Llc | Gas bubble sensor |
US11965763B2 (en) | 2021-11-12 | 2024-04-23 | Mozarc Medical Us Llc | Determining fluid flow across rotary pump |
US11944733B2 (en) | 2021-11-18 | 2024-04-02 | Mozarc Medical Us Llc | Sodium and bicarbonate control |
Also Published As
Publication number | Publication date |
---|---|
US8521482B2 (en) | 2013-08-27 |
WO2010096659A1 (en) | 2010-08-26 |
US20130317795A1 (en) | 2013-11-28 |
EP2398529A1 (en) | 2011-12-28 |
EP2398529B1 (en) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8521482B2 (en) | Simulation of patient drain phase in peritoneal dialysis | |
US9348975B2 (en) | Optimizing therapy outcomes for peritoneal dialysis | |
EP2280746B1 (en) | Smart patient transfer set for peritoneal dialysis | |
JP7627394B2 (en) | Drain and fill logic for automated peritoneal dialysis. | |
US9943632B2 (en) | Drain and fill logic for automated peritoneal dialysis | |
US8142649B2 (en) | Method for optimizing tidal therapies employing ultrafiltrate trending | |
US11883576B2 (en) | Peritoneal dialysis intracycle osmotic agent adjustment | |
CN107729709A (en) | Adjusted in adaptive peritoneal dialysis session for overall session optimization | |
MXPA02007765A (en) | Method and apparatus for monitoring and controlling peritoneal dialysis therapy. | |
US20110009810A1 (en) | Peritoneal dialysis therapy with large dialysis solution volumes | |
EP3506963A1 (en) | Apparatus for providing automated peritoneal dialysis | |
US11951242B2 (en) | Method for trending automated peritoneal dialysis treatments | |
Stewart et al. | Is there any role for sodium modeling in the prevention of intradialytic hypotension in patients with large interdialytic fluid gains? | |
López‐Herce et al. | Continuous venovenous renal replacement therapy with a pulsatile tubular blood pump: analysis of efficacy parameters | |
WO2022108915A1 (en) | Weight-based peritoneal dialysis system including a drain trolley |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAXTER INTERNATIONAL INC., ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AKONUR, ALP;LO, YING-CHENG;REEL/FRAME:022322/0023 Effective date: 20090212 Owner name: BAXTER HEALTHCARE S.A., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AKONUR, ALP;LO, YING-CHENG;REEL/FRAME:022322/0023 Effective date: 20090212 |
|
AS | Assignment |
Owner name: BAXTER HEALTHCARE S.A., SWITZERLAND Free format text: CHANGE OF CORPORATE ADDRESS;ASSIGNOR:BAXTER HEALTHCARE S.A.;REEL/FRAME:030874/0072 Effective date: 20090814 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |